Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh

Inclusion Criteria: -Patients of 12 years and older with probable PKDL (skin lesions strongly suggestive of PKDL with exclusion of other skin diseases, a history of VL treatment and a positive serological rK39 test) Exclusion Criteria: * PKDL and concurrent VL * Prior treatment for PKDL * On medication with a side effect profile overlapping with that of AmBisome * A known hypersensitivity to AmBisome * Pregnant and lactating women, * Known cardiac disease, hepatic impairment or another severe chronic underlying disease -Renal impairment (baseline serum creatinine \> 1.3 mg/dL) * Serum potassium \<3.5mmol/L at baseline